Home › Steatotic Liver Disease › Arizona › Tucson
Steatotic Liver Disease clinical trials in Tucson, AZ
10 studies for Steatotic Liver Disease are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Tucson
- 89bio Clinical Study Site, Tucson
- 89bio Clinical Study Site, Tucson
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Tucson
- 89bio Clinical Study Site, Tucson
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
RecruitingPhase 2
- Arizona Liver Health - Tucson, Tucson
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
RecruitingPhase 2
- Adobe Clinical Research, Tucson
- Arizona Liver Health - Tucson, Tucson
- Del Sol Research Management, LLC, Tucson
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
- The Institute for Liver Health II dba Arizona Clinical Trials - Tucson, Tucson
- Del Sol Research Management, LLC, Tucson
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
- Akero Clinical Study Site, Tucson
- Akero Clinical Study Site, Tucson
- Akero Clinical Study Site, Tucson
- and 1 more
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 2
- Adobe Clinical Research, LLC, Tucson
- Arizona Liver Health - Tucson, Tucson
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RecruitingPhase 2
- GSK Investigational Site, Tucson
- GSK Investigational Site, Tucson
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RecruitingPhase 3
- GSK Investigational Site, Tucson
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RecruitingPhase 2
- GSK Investigational Site, Tucson
About Steatotic Liver Disease
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
More about Steatotic Liver Disease on MedlinePlus
Steatotic Liver Disease trials in other cities
- San Antonio, TX17 studies
- Miami, FL16 studies
- New York City, NY16 studies
- San Diego, CA14 studies
- Houston, TX13 studies
- Austin, TX13 studies
- Richmond, VA12 studies
- Chandler, AZ10 studies
- St. Louis, MO9 studies
- Dallas, TX9 studies
- Hialeah, FL9 studies
- Orlando, FL9 studies
Other studies in Tucson
- Breast Cancer20 studies
- Obesity18 studies
- Non-Small Cell Lung Cancer17 studies
- Overweight15 studies
- Metastatic Cancer14 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Colorectal Cancer11 studies
- Prostate Cancer11 studies
- Type 2 Diabetes11 studies
- Heart Failure10 studies
- High Blood Pressure10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.